Anti-Müllerian Hormone: The Peptide Biomarker That Predicts Ovarian Reserve and Fertility
Anti-Müllerian hormone (AMH) serves as a reliable blood marker of ovarian reserve, with clinical applications in PCOS diagnosis, IVF planning, and predicting menopause timing.
Quick Facts
What This Study Found
The review outlines AMH's key clinical roles:
• AMH is produced by granulosa cells of growing follicles before they become FSH-dependent, making it a direct marker of the ovarian follicle pool
• AMH serum concentration strongly correlates with ovarian reserve quantity and reflects ovulation potential
• In males, Sertoli cells produce high AMH levels that suppress Müllerian duct development during embryonic sex determination, maintaining high levels until puberty
• In females, AMH production begins in the second half of fetal life, declines through reproductive years, drops severely at menopause, and eventually becomes undetectable
• Clinical applications include PCOS diagnosis and pathogenesis assessment, artificial reproductive technology (IVF) planning, and prediction of menopause or premature ovarian failure
Key Numbers
How They Did This
This is a narrative review published in the Journal of Clinical Medicine that synthesizes existing literature on AMH biology and clinical applications across reproductive medicine, embryology, and endocrinology.
Why This Research Matters
AMH testing has revolutionized reproductive medicine by giving women and their doctors objective data about fertility potential. Before AMH, assessing ovarian reserve required invasive procedures or less reliable markers. A simple blood test that predicts how many eggs remain — and how a woman will respond to IVF stimulation — empowers better family planning decisions and more personalized fertility treatment.
The Bigger Picture
AMH sits at the intersection of peptide biology and reproductive medicine. As more women delay childbearing, understanding ovarian reserve has become a pressing clinical need. AMH testing is now standard practice in fertility clinics worldwide and is increasingly offered as part of routine women's health screening. The peptide's unique expression pattern — produced only by pre-selected follicles — makes it uniquely informative compared to other reproductive hormones like FSH or estradiol, which fluctuate throughout the menstrual cycle.
What This Study Doesn't Tell Us
As a narrative review, this presents a synthesis of existing knowledge rather than new data. AMH levels can vary between assay platforms, and interpretation requires clinical context — a single AMH level doesn't definitively determine fertility or infertility. The review doesn't address recent research on AMH-based contraception or AMH's potential roles beyond reproduction. Individual variability in AMH levels means population-level correlations don't always apply to individual patients.
Questions This Raises
- ?Could AMH-targeted therapies be developed to extend the reproductive window or treat premature ovarian failure?
- ?How accurate is AMH alone versus combined biomarker panels for predicting IVF success?
- ?Should AMH testing be included in routine health screening for all women of reproductive age?
Trust & Context
- Key Stat:
- Strong correlation with ovarian reserve AMH blood levels reliably reflect the number of remaining eggs, making it the go-to biomarker for fertility assessment and IVF planning
- Evidence Grade:
- This is a narrative review summarizing well-established clinical science on AMH. The clinical utility of AMH testing is supported by extensive evidence and is standard practice in reproductive medicine worldwide. The review itself does not generate new data.
- Study Age:
- Published in 2022, this review captures the current clinical consensus on AMH utility. AMH testing is well-established and the fundamental science hasn't changed significantly since publication.
- Original Title:
- Clinical Utilities of Anti-Müllerian Hormone.
- Published In:
- Journal of clinical medicine, 11(23) (2022)
- Authors:
- Russell, Nicole, Gilmore, Andrea, Roudebush, William E
- Database ID:
- RPEP-06466
Evidence Hierarchy
Frequently Asked Questions
What does an AMH blood test tell you about fertility?
AMH levels reflect your ovarian reserve — essentially how many eggs you have remaining. Higher AMH suggests more eggs and generally better fertility potential, while very low AMH may indicate diminished ovarian reserve. It's one of the most reliable blood markers used in fertility assessment and IVF planning.
Is AMH used to diagnose PCOS?
Yes. Women with polycystic ovarian syndrome (PCOS) typically have elevated AMH levels because they have an unusually high number of small follicles. AMH testing is used alongside other criteria to diagnose PCOS and assess its severity, helping guide treatment decisions.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06466APA
Russell, Nicole; Gilmore, Andrea; Roudebush, William E. (2022). Clinical Utilities of Anti-Müllerian Hormone.. Journal of clinical medicine, 11(23). https://doi.org/10.3390/jcm11237209
MLA
Russell, Nicole, et al. "Clinical Utilities of Anti-Müllerian Hormone.." Journal of clinical medicine, 2022. https://doi.org/10.3390/jcm11237209
RethinkPeptides
RethinkPeptides Research Database. "Clinical Utilities of Anti-Müllerian Hormone." RPEP-06466. Retrieved from https://rethinkpeptides.com/research/russell-2022-clinical-utilities-of-antimllerian
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.